Predicting clinical benefit of immunotherapy by antigenic or functional mutations affecting tumour immunogenicity
Predicting response to cancer immunotherapy is still a challenge. Here, the authors show that their method of predicting MHC-binding peptides, combined with profiling anti-immunogenic mutations, can better predict the clinical benefit of immunotherapy.
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Nature Portfolio
2020
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/81e385970f0841be95673eae17dd1b1b |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|